Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Source: View publication →
In patients with type 2 diabetes and established cardiovascular disease, the once-weekly GLP-1 receptor agonist albiglutide significantly reduced the risk of major adverse cardiovascular events compared to placebo.
Key Findings
Study Design
Study Limitations
Clinical Significance
The Harmony Outcomes trial reinforced the hypothesis that human-sequence GLP-1 receptor agonists confer substantial cardioprotection (specifically reducing ischemic events) in patients with type 2 diabetes. While albiglutide's clinical utility was preempted by its market withdrawal, these results strengthened the evidence for a class effect regarding atherosclerotic risk reduction, subsequently shaping major society guidelines prioritizing GLP-1 RAs in patients with diabetes and established ASCVD.
Historical Context
Initiated in response to FDA mandates following the rosiglitazone controversy, Harmony Outcomes tested the cardiovascular safety of albiglutide. Paradoxically, due to poor sales and competition from other GLP-1 RAs, GlaxoSmithKline withdrew the drug from the market globally in 2017 while the trial was still ongoing. By the time this landmark trial read out in 2018 demonstrating clear superiority and cardioprotection, the drug was no longer available to patients, leading to calls from trial investigators for the manufacturer to return the medication to clinical use.
Guided Discussion
High-yield insights from every perspective
How does the mechanism of action of GLP-1 receptor agonists like albiglutide differ from DPP-4 inhibitors, and why might GLP-1 RAs demonstrate cardiovascular risk reduction while DPP-4 inhibitors generally have not?
Key Response
GLP-1 RAs provide pharmacological, supra-physiological levels of GLP-1, leading to robust weight loss, blood pressure reduction, and direct beneficial effects on endothelial and myocardial receptors. In contrast, DPP-4 inhibitors only prevent the breakdown of endogenous GLP-1, achieving physiological levels that improve glycemic control but lack the pleiotropic effects required for significant cardiovascular risk reduction.
A patient with T2DM and a prior myocardial infarction is currently on metformin and a high-intensity statin with an HbA1c of 7.2%. Based on the Harmony Outcomes trial and similar studies, how should you adjust their diabetes regimen, and what is the primary goal of this adjustment?
Key Response
The addition of a GLP-1 RA (or SGLT2i) with proven cardiovascular benefit is indicated for secondary prevention of major adverse cardiovascular events (MACE) in this patient, independent of their baseline HbA1c or individualized glycemic targets. The primary goal is reducing the risk of recurrent MI, stroke, or CV death, rather than merely lowering glucose.
Albiglutide is a human GLP-1 dimer fused to albumin. How does this structural pharmacology compare to exendin-4 based GLP-1 RAs (e.g., lixisenatide, exenatide), and how do these structural differences influence the consistency of cardiovascular benefits seen across the class?
Key Response
GLP-1 RAs are broadly divided into exendin-4 derivatives (e.g., exenatide, lixisenatide) and human GLP-1 analogues (e.g., albiglutide, liraglutide, semaglutide, dulaglutide). Trials like ELIXA and EXSCEL showed neutral or borderline CV outcomes for exendin-based agents, whereas human GLP-1 analogues, including albiglutide in Harmony Outcomes, have consistently demonstrated significant MACE reduction. This supports a structural subclass effect driven by homology to native GLP-1 and longer half-lives.
Albiglutide demonstrated a significant reduction in MACE in Harmony Outcomes, yet the manufacturer withdrew the drug from the market globally for commercial reasons prior to the study's publication. How does this 'orphan' positive trial impact clinical decision-making regarding the class-effect versus individual-drug-effect debate in cardiovascular risk reduction?
Key Response
The positive results of Harmony Outcomes strongly support the hypothesis that cardiovascular benefit is a class effect among long-acting, human GLP-1 analogues. Even though albiglutide cannot be prescribed, its data reinforces the attending physician's confidence in prescribing available alternatives (like dulaglutide or semaglutide) for secondary prevention, knowing the mechanism of risk reduction is highly conserved across the human-based analogues.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The Harmony Outcomes trial utilized an event-driven design targeting 611 first occurrences of the primary composite MACE endpoint. What are the statistical advantages and limitations of this event-driven approach compared to a fixed follow-up duration, particularly regarding the power to detect differences in individual components of the composite endpoint?
Key Response
An event-driven design ensures adequate statistical power for the primary composite outcome regardless of lower-than-expected event rates, making the trial highly efficient. However, a major limitation is that the trial stops once the target number of primary events is reached, often leaving it underpowered to definitively assess treatment effects on individual components (such as cardiovascular death alone) or rare but important secondary safety endpoints.
In the critical appraisal of the Harmony Outcomes trial, how does the high background rate of standard-of-care cardiovascular medications (such as statins and RAS inhibitors) impact the required sample size and the interpretation of the drug's incremental efficacy, and what potential biases could arise if regional adherence to these baseline therapies varied significantly across multinational sites?
Key Response
A highly treated background population lowers the baseline risk of MACE, reducing the expected event rate and requiring a larger sample size or longer duration to accumulate the necessary events. Furthermore, if regional variations in standard-of-care adherence exist and correlate with specific treatment arms or dropout rates, it could introduce significant confounding, threatening the trial's external validity and the generalizability of the incremental relative risk reduction.
Current ADA/EASD guidelines recommend the use of specific GLP-1 RAs with proven cardiovascular benefit in patients with T2DM and established ASCVD. Given that albiglutide is no longer commercially available, how should guideline committees synthesize the Harmony Outcomes data to formulate recommendations, and does this trial provide sufficient evidence to upgrade the level of recommendation for the entire class rather than specific agents?
Key Response
While guidelines cannot recommend an unavailable drug, the Harmony Outcomes trial is crucial for meta-analyses that elevate the overall strength of evidence (Level A) for long-acting GLP-1 RAs. It confirms that MACE reduction is not an isolated finding of a single agent (e.g., liraglutide) but a robust property of the human GLP-1 analogue subclass, justifying broad, high-strength recommendations for their prioritized use in ASCVD patients.
Clinical Landscape
Noteworthy Related Trials
LEADER Trial
Tested
Liraglutide up to 1.8 mg daily
Population
Patients with type 2 diabetes and high cardiovascular risk
Comparator
Placebo
Endpoint
3-point MACE (CV death, nonfatal MI, nonfatal stroke)
SUSTAIN-6
Tested
Semaglutide 0.5 mg or 1.0 mg once weekly
Population
Patients with type 2 diabetes and high cardiovascular risk
Comparator
Placebo
Endpoint
3-point MACE (CV death, nonfatal MI, nonfatal stroke)
REWIND Trial
Tested
Dulaglutide 1.5 mg once weekly
Population
Patients with type 2 diabetes with or without previous cardiovascular disease
Comparator
Placebo
Endpoint
3-point MACE (CV death, nonfatal MI, nonfatal stroke)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis